Xilio Therapeutics (XLO) Earnings Analysis

Xilio Therapeutics (XLO) next reports earnings on 2026-08-13, consensus EPS -0.59 USD. Last quarter (2026-03-23) it beat with EPS -0.85 USD vs -1.68 USD est (+49.4%). It has beaten estimates in 6/6 recent quarters (100%). Trailing P/E -1.54.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does XLO next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.59 USD
Revenue estimate0.01B

XLO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-23-0.85 USD-1.68 USD+49.4%Beat
2025-11-13-0.03 USD-0.4466 USD+93.3%Beat
2025-08-14-0.16 USD-1.1032 USD+85.5%Beat
2025-05-08-0.18 USD-2.6978 USD+93.3%Beat
2025-03-11-0.2 USD-3.0338 USD+93.4%Beat
2024-11-07-0.22 USD-0.25 USD+12%Beat

Beat rate: 6/6 (100%) over reported quarters with consensus data.

XLO valuation and analyst view

Trailing P/E-1.54
Trailing EPS-0.19147 USD
Price / book19.11
Dividend yield0.00%
Market cap0.06B
Analyst consensusBuy (3 buy / 0 hold / 0 sell)

Related research pages

Frequently asked questions

When is Xilio Therapeutics (XLO)'s next earnings date?

Xilio Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.59 USD and revenue estimate of 0.01B.

Did XLO beat earnings last quarter?

In its 2026-03-23 report, XLO posted EPS of -0.85 USD versus a -1.68 USD estimate — a beat of 49.4%.

What is XLO's earnings track record?

Over the last 6 reported quarters with consensus data, XLO beat estimates 6 times (100%).

What is XLO's current P/E ratio and EPS?

XLO trades at a trailing P/E of -1.54 on trailing EPS of -0.19146614003894655 USD.

What do analysts rate XLO?

Analyst consensus is "Buy" across 3 ratings (0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell).